Manufacturing and packing of IMP for the IM Woman Trial due to commence in March 2023. A randomised, triple-blind, three-arm, non-inferiority trial to assess the efficacy and safety of intramuscular tranexamic acid compared to intravenous tranexamic acid and placebo in women having vvaginal and caesarean section births. Three arms include experimental treatment (IM TXA), reference treatment/active control (IV TXA), and placebo control (0.9% sodium chloride solution). Treatment Kit Boxes required 4 campaigns with approximately 10,000 patient packs per campaign. Recruitment period is 24 months - campaign approximately once every 6 months.
05/01/2022 13:00:00
33600000-6 Pharmaceutical products
33698000-9 Clinical products
44617100-9 Cartons
33141310-6 Syringes
33621000-9 Medicinal products for the blood and blood-forming organs
33621200-1 Antihaemorrhagics
39299100-5 Glass ampoules
33141320-9 Medical needles
79920000-9 Packaging and related services
London School of Hygiene & Tropical Medicine
Keppel Street,
WC1E 7HT
London
United Kingdom
View profile
| Notice | Date of dispatch |
|---|---|
| Live Opportunity (Contracts Finder) | 22/11/2021 19:01 |
| Contract notice (FTS) | |
| Awarded Contract (Contracts Finder) | 21/08/2023 16:45 |
| Contract award notice (FTS) |
Sharp Clinical Services (UK) Ltd, organisation no: 2234557